Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CYCC
- CUSIP: N/A
- Web: www.cyclacel.com
Average Prices:- 50 Day Moving Avg: $1.69
- 200 Day Moving Avg: $3.66
- 52 Week Range: $1.56 - $10.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.09
- P/E Growth: 0.00
Profitability:- Net Margins: -1,128.13%
- Return on Equity: -68.88%
- Return on Assets: -50.80%
Debt:- Current Ratio: 3.72%
- Quick Ratio: 3.72%
Misc:- Average Volume: 496,364 shs.
- Beta: 3.45
Frequently Asked Questions for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
What is Cyclacel Pharmaceuticals' stock symbol?
Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."
When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?
Shares of Cyclacel Pharmaceuticals reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.
How were Cyclacel Pharmaceuticals' earnings last quarter?
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.50) earnings per share for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 68.88% and a negative net margin of 1,128.13%. View Cyclacel Pharmaceuticals' Earnings History.
Are investors shorting Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 441,830 shares, a drop of 35.8% from the August 15th total of 688,157 shares. Based on an average daily volume of 239,223 shares, the days-to-cover ratio is currently 1.8 days. Approximately 3.9% of the company's shares are sold short.
Who are some of Cyclacel Pharmaceuticals' key competitors?
Some companies that are related to Cyclacel Pharmaceuticals include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT) and GW Pharmaceuticals PLC (GWPH).
Who are Cyclacel Pharmaceuticals' key executives?
Cyclacel Pharmaceuticals' management team includes the folowing people:
- David Charles U'Prichard Ph.D., Independent Chairman of the Board
- Spiro George Rombotis, President, Chief Executive Officer, Director
- Christopher S. Henney Ph.D., Independent Vice Chairman of the Board
- Paul McBarron, Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
- Judy H. Chiao M.D., Vice President - Clinical Development and Regulatory Affairs
- John Michael Middlecott Banham, Independent Director
- Samuel L. Barker Ph.D., Independent Director
- Gregory T. Hradsky, Independent Director
- Lloyd M. Sems, Independent Director
Who owns Cyclacel Pharmaceuticals stock?
Cyclacel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include
EASTERN CAPITAL LTD
(17.70%), Tang Capital Management LLC (0.00%), Vanguard Group Inc. (0.00%) and Dimensional Fund Advisors LP (0.00%). Company insiders that own Cyclacel Pharmaceuticals stock include Eastern Capital Ltd and Kevin C Tang. View Institutional Ownership Trends for Cyclacel Pharmaceuticals.
Who sold Cyclacel Pharmaceuticals stock? Who is selling Cyclacel Pharmaceuticals stock?
How do I buy Cyclacel Pharmaceuticals stock?
Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cyclacel Pharmaceuticals' stock price today?
One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $1.71.
MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/12/2016 | HC Wainwright | Reiterated Rating | Buy | | N/A |  |
(Data available from 9/20/2015 forward)
Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)Earnings History by Quarter for Cyclacel Pharmaceuticals (NASDAQ CYCC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2017 | Q2 2017 | | ($0.50) | | | View | Listen | |
| 5/11/2017 | Q1 2017 | | ($0.38) | | | View | N/A | |
| 3/28/2017 | Q4 2016 | ($0.73) | ($0.69) | $0.21 million | $0.28 million | View | N/A | |
| 11/14/2016 | Q316 | ($0.94) | ($0.86) | $0.42 million | $0.21 million | View | N/A | |
| 8/10/2016 | Q216 | | ($1.01) | | $0.22 million | View | Listen | |
| 5/11/2016 | Q116 | | ($0.09) | $512.00 million | $139.00 million | View | Listen | |
| 3/24/2016 | Q4 | ($0.08) | ($0.10) | $0.51 million | $0.42 million | View | Listen | |
| 11/12/2015 | Q315 | ($0.09) | ($0.08) | $0.30 million | $0.72 million | View | Listen | |
| 8/11/2015 | Q215 | | ($0.10) | | $0.30 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.25) | ($0.19) | | $0.51 million | View | Listen | |
| 3/24/2015 | Q414 | ($0.26) | ($0.21) | | $0.25 million | View | N/A | |
| 11/11/2014 | Q314 | ($0.26) | ($0.22) | | $0.74 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.28) | ($0.22) | | $0.36 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.24) | ($0.25) | | $0.40 million | View | N/A | |
| 3/25/2014 | Q413 | ($0.33) | ($0.19) | $0.09 million | $0.30 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.31) | ($0.31) | | | View | Listen | |
| 8/14/2013 | Q2 2013 | | ($0.10) | $0.03 million | $0.26 million | View | N/A | |
| 5/13/2013 | Q1 2013 | | ($1.18) | | | View | N/A | |
| 11/12/2012 | Q312 | | ($0.37) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-1.57 EPS
Dividend History by Quarter for Cyclacel Pharmaceuticals (NASDAQ CYCC)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/9/2016 | Annual | $0.15 | | 7/13/2016 | 7/17/2016 | 8/1/2016 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 6.48%
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/19/2017 | Eastern Capital Ltd | Major Shareholder | Buy | 850,000 | $2.00 | $1,700,000.00 | |
| 2/23/2017 | Kevin C Tang | Major Shareholder | Buy | 134,200 | $4.34 | $582,428.00 | |
| 11/20/2014 | Sam L Barker | Director | Buy | 3,100 | $3.00 | $9,300.00 | |
| 5/21/2013 | Lloyd Sems | Director | Buy | 33,333 | $3.00 | $99,999.00 | |
| 5/21/2013 | Paul Mcbarron | CFO | Buy | 12,948 | $3.03 | $39,232.44 | |
| 5/21/2013 | Spiro George Rombotis | Insider | Buy | 100,000 | $3.00 | $300,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
| Source: |
|
| Date | Headline |
|---|
 | Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 10% Yield Mark
www.thestreet.com - September 19 at 5:44 PM |
 | Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%
www.americanbankingnews.com - September 17 at 1:20 AM |
 | Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation
finance.yahoo.com - September 13 at 7:01 PM |
 | Cyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 6:24 PM |
| Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%
www.americanbankingnews.com - August 14 at 2:38 AM |
| Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM |
| Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:58 PM |
| Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 4:00 AM |
 | Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:55 PM |
 | Cyclacel Pharma (CYCC) Reports Selection of Recommended ... - StreetInsider.com
www.streetinsider.com - August 7 at 11:06 PM |
| Part 2 of study will focus on cyclin E amplified drug resistant solid tumors
globenewswire.com - August 7 at 6:05 PM |
| Form 8-K Cyclacel Pharmaceuticals For: Aug 07
www.streetinsider.com - August 7 at 6:05 PM |
| Cyclacel Pharmaceuticals to Release Second Quarter 2017 ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 6:32 PM |
| Cyclacel Announces Closing of $15.2 Million Underwritten Public ... - GlobeNewswire (press release)
globenewswire.com - July 22 at 12:29 AM |
 | Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option - Nasdaq
www.nasdaq.com - July 21 at 7:27 PM |
| Insider Buying: Cyclacel Pharmaceuticals, Inc. (CYCC) Major Shareholder Purchases 850,000 Shares of Stock
www.americanbankingnews.com - July 21 at 7:10 PM |
| Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc.
finance.yahoo.com - July 20 at 7:45 PM |
| Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
globenewswire.com - July 19 at 6:53 PM |
| Cyclacel Pharmaceuticals Inc (CYCC) Short Interest Update
www.americanbankingnews.com - May 13 at 7:44 AM |
 | 22 Stocks Moving In Friday's Pre-Market Session - Benzinga
www.benzinga.com - May 12 at 5:09 PM |
| Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 5:09 PM |
| Cyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 3:12 PM |
| Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 3:20 AM |
| Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 5:18 PM |
| Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
feeds.benzinga.com - May 5 at 7:43 AM |
| Positive Media Coverage Somewhat Likely to Impact Cyclacel Pharmaceuticals (CYCC) Stock Price
www.americanbankingnews.com - April 29 at 9:35 PM |
| Cyclacel Pharmaceuticals Inc (CYCC) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 26 at 7:24 PM |
| Cyclacel Pharmaceuticals (CYCC) Receives News Impact Score of 0.04
www.americanbankingnews.com - April 25 at 4:51 PM |
| Company News for April 11, 2017
finance.yahoo.com - April 11 at 12:58 PM |
| ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:19 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-Yingli Green, Calix, Hertz Global, Cyclacel Pharma - Nasdaq
www.nasdaq.com - April 3 at 5:02 PM |
 | Cyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News - RTT News
www.rttnews.com - April 3 at 5:02 PM |
 | Cyclacel's CYC065 Succeeds in Lung Cancer Study
www.investopedia.com - April 3 at 5:02 PM |
| Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by ... - Yahoo Finance
finance.yahoo.com - April 2 at 9:32 PM |
| Edited Transcript of CYCC earnings conference call or presentation 28-Mar-17 8:30pm GMT
finance.yahoo.com - March 29 at 11:54 AM |
| After-Hours Earnings Report for March 28, 2017 : PLAY, VRNT, OLLI, SONC, WLB, AST, IZEA, CYCC - Nasdaq
www.nasdaq.com - March 28 at 4:23 PM |
| CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 28 at 4:23 PM |
| Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 12:18 PM |
| CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 13 at 4:43 PM |
| Cyclacel Pharma (CYCC) CDK Inhibitor CYC065 Causes Anaphase Catastrophe Featured in JNCI Publication - StreetInsider.com
www.streetinsider.com - March 9 at 5:11 PM |
| Cyclacel Pharmaceuticals: Is There Anything Left In The Tank? - Seeking Alpha
seekingalpha.com - March 9 at 5:11 PM |
| Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI
finance.yahoo.com - March 7 at 12:04 PM |
| 7:03 am Cyclacel Pharma announces the publication of a peer-reviewed journal article featuring the company's cyclin dependent kinase 2/9 (CDK2/9) inhibitors; 'preclinical data demonstrated that both Cyclacel's CYC065 and CCT68127 demonstrat
finance.yahoo.com - March 7 at 12:04 PM |
| Cyclacel Plunges on Leukemia Drug Failure (CYCC)
www.investopedia.com - February 24 at 12:00 PM |
| Cyclacel Tanks on Leukemia Drug Failure
www.investopedia.com - February 24 at 12:00 PM |
| Cyclacel Pharma (CYCC) Pivotal Phase 3 SEAMLESS Study in Elderly Patients With AML Doesn't Meet Primary Endpoint
www.streetinsider.com - February 23 at 9:39 PM |
 | 6:57 am Cyclacel Pharma announces its Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia did not meet its primary endpoint
us.rd.yahoo.com - February 23 at 9:39 PM |
| Cyclacel's leukemia drug for elderly patients fails in key study
us.rd.yahoo.com - February 23 at 9:39 PM |
 | Cyclacel's stock plunges after disappointing trial results of its cancer treatment
us.rd.yahoo.com - February 23 at 9:39 PM |
| CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - February 23 at 9:39 PM |
Cyclacel Pharmaceuticals (CYCC) Chart for Wednesday, September, 20, 2017
